Evaluation of correlation between expression of P53 and Malondialdehyde levels in prostate cancer patients.
The analytical study was conducted at the National University of Sciences and Technology, Islamabad, Pakistan from Nov 2012 to Nov 2013 to find out, correlate and assess negative correlation of serum malondialdehyde (MDA) with expression of p53 gene, and comprised 32 samples. Expression of p53 and MDA levels were determined by real time quantitative polymerase chain reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA) technique respectively. Mean value of MDA in prostate carcinoma (CaP) and control group were compared, and the difference was statistically significant (p=0.002). Mean cycle threshold (CT) value of CaP was compared with control group, and the difference was statistically significant (p0.05) compared to the controls. Mean p53 expression in CaP patients was 19.17 +- 2.6 and in the control group it was 14.36 +- 2.01 (p0.05). Outcome illustrated that MDA and expression of p53 had an inverse relationship (Table-2).
Tumour cells usually have an imbalance redox status resulting in damage to DNA, protein and lipids as well. In our findings, MDA levels were significantly high in Pakistani population of CaP compared to normal controls. In Israeli population the results were quite different, localised CaP had no statistically significant rise in MDA levels. Only the metastatic disease of CaP had statistically significant high value in MDA levels.20 In 2011, Brazilian population also showed the same results that MDA levels was not statistically significant with normal control.21 In 2006, significant increase in MDA was seen in Turkish population.22 A similar pattern was also found in both Turkish and Macedonian population in 2009.23 Another study in Turkish population also showed that the levels of MDA were significantly higher in plasma in CaP.24 Another study illustrated that blood MDA levels were statistically significantly high in localised prostate cancer compared to normal controls.18
Our results showed that MDA level was significantly high yet it is not significant if we compare the Gleason scoring with the normal control. Another study illustrated that although blood MDA levels were significantly high yet it was not the same in tissue with Gleason sum in CaPpatients.18 Significantly high level of MDA was observed in Indian population.25 According to a study in Indian population, MDA levels were significantly higher compared to the controls.26 MDA may be used as a bio-marker for CaP in Pakistani population. MDA is not a useful biomarker in different Gleason scores of prostate cancer except Gleason score 8. In 2012, it was found that MDA was statistically increased with progression of CaP and Gleason score.26 Further studies should be planned on levels of MDA in different Gleason scores of CaP with larger population groups.
The p53 gene was involved in numerous pathways, which were interlinked for progression of CaP. Many studies have revealed that p53 is involved in different cancers. Many biological pathways were affected by alteration of p53 gene. In recent years, p53 was also found to be at the hub of significantly predicting biological pathways.5 A similar study was done in 2012, according to which, functional status of tumour suppressor p53 was important in progression of CaP.4 It was detected that p53 was genetically altered in histological localised organ-confined CaP as well as non-organ-confined CaP and distant metastasis.27 Our results suggest that expression of p53 was significantly decreased in CaP. According to the outcomes of our experiments, p53 may be used as biological marker for CaP. Similar results were also observed in an earlier study which showed that a positive expression of p53 messenger ribonucleic acid (mRNA) is involved in CaP.28
Our study focussed on correlation of expression of p53 and MDA in CaP group. Results obtained appeared statistically non-significant, but it has a weak inverse correlation between expression of p53 and MDA in CaP. It was our first step to find the actual role of expression of p53 in CaP. More research work should be undertaken to elucidate the actual mechanism involved in CaP.
MDA may be utilised as a biological marker of CaP in future. It is also appears that MDA may have some role in the progression of disease. There was a significant relationship between MDA and Gleason score 8.
Conflict of Interest: None.
Source of Funding: National University of Sciences and Technology, Islamabad.
1. Zhang L, Shao N, Yu Q, Hua L, Mi Y, Feng N. Association between p53 Pro72Arg polymorphism and prostate cancer risk: a meta-analysis. J Biomed Res. 2011; 25:25-32.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. Can J Clin. 2012; 62:220-41.
3. Corkum M, Hayden JA, Kephart G, Urquhart R, Schlievert C, Porter G. Screening for new primary cancers in cancer survivors compared to non-cancer controls: a systematic review and meta-analysis. J Can Surviv. 2013; 7:455-63.
4. Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell cycle. 2012; 11:4579-88.
5. Sethi S, Kong D, Land S, Dyson G, Sakr WA, Sarkar FH. Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer. Am J Trans Res. 2013; 5:200-11.
6. Grant K, Lindenberg ML, Shebel H, Pang Y, Agarwal HK, Bernardo M, et al. Functional and molecular imaging of localized and recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40:S48-59.
7. Pathak S, Singh R, Verschoyle RD, Greaves P, Farmer PB, Steward WP, et al. Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo. Cancer lett. 2008; 261:74-83.
8. Ani I, Costaldi M, Abouassaly R. Metastatic prostate cancer with malignant ascites: A case report and literature review. Can Urol Assoc J. 2013; 7:E248-50.
9. Piantino CB, Reis ST, Viana NI, Silva IA, Morais DR, Antunes AA, et al. Prima-1 induces apoptosis in bladder cancer cell lines by activating p53. Clinics (Sao Paulo). 2013; 68:297-303.
10. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. Can J Clin. 2010; 60:277-300.
11. Bashir MN, Malik MA. Case-Control Study of Diet and Prostate Cancer in a Rural Population of Faisalabad. Pakistan Asian Pacific J Can Prev. 2015; 16:2375-8.
12. Bhurgri Y, Kayani N, Pervez S. Incidence and trends of prostate cancer in Karachi South. Asian Pac J Cancer Prev. 1995; 10:45-8.
13. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Sci. 2007; 318:1108-13.
14. D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, et al. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology. 2008; 71:933-7.
15. Merendino RA, Salvo F, Saija A, Di Pasquale G, Tomaino A, Minciullo PL, et al. Malondialdehyde in benign prostate hypertrophy: a useful marker? Mediators Inflamm. 2003; 12:127-8.
16. Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, et al. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate. 2013; 73:418-27.
17. Dean JL, Knudsen KE. The role of tumor suppressor dysregulation in prostate cancer progression. Curr Drug Targets. 2013; 14:460-71.
18. Dillioglugil MO, Mekik H, Muezzinoglu B, Ozkan TA, Demir CG, Dillioglugil O. Blood and tissue nitric oxide and malondialdehyde are prognostic indicators of localized prostate cancer. Int Urol Nephrol. 2012; 44:1691-6.
19. Prostate Cancer Early Detection, Diagnosis and Staging,'American Cancer Society. [onlie] [cited 2016 MAy 2]. Available from: URL: https://www.cancer.org/content/dam/CRC/PDF/Public/8795.00.p df.
20. Yossepowitch O, Pinchuk I, Gur U, Neumann A, Lichtenberg D, Baniel J. Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol. 2007; 178:1238-43.
21. Battisti V, Maders LD, Bagatini MD, Reetz LG, Chiesa J, Battisti IE, et al. Oxidative stress and antioxidant status in prostate cancer patients: relation to Gleason score, treatment and bone metastasis. Biomedicine and pharmacotherapy Biomed Pharmacother. 2011; 65:516-24.
22. Ozmen H, Erulas FA, Karatas F, Cukurovali A, Yalcin O. Comparison of the concentration of trace metals (Ni, Zn, Co, Cu and Se), Fe, vitamins A, C and E, and lipid peroxidation in patients with prostate cancer. Clin Chem Lab Med. 2006; 44:175-9.
23. Arsova-Sarafinovska Z, Eken A, Matevska N, Erdem O, Sayal A, Savaser A, et al. Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem. 2009; 42:1228-35.
24. Guzel S, Kiziler L, Aydemir B, Alici B, Ataus S, Aksu A, et al. Association of Pb, Cd, and Se concentrations and oxidative damage-related markers in different grades of prostate carcinoma. Bio Trace Elem Res. 2012; 145:23-32.
25. Srivastava DS, Mittal RD. Free radical injury and antioxidant status in patients with benign prostate hyperplasia and prostate cancer. Indian J Clin Biochem. 2005; 20:162-5.
26. Pande D, Negi R, Karki K, Dwivedi US, Khanna RS, Khanna HD. Simultaneous progression of oxidative stress, angiogenesis, and cell proliferation in prostate carcinoma. Urol Oncol. 2013; 31:1561-6.
27. Moul JW, Merseburger AS, Srivastava S. Molecular markers in prostate cancer: the role in preoperative staging. Clin Prostate Can. 2002; 1:42-50.
28. Ding GF, Xu YF, Yang ZS, Ding YL, Fang HF, Zhao HP. Coexpression of the mutated BRCA1 mRNA and p53 mRNA and its association in Chinese prostate cancer. Urol Oncol. 2011; 29:145-9.
|Printer friendly Cite/link Email Feedback|
|Publication:||Journal of Pakistan Medical Association|
|Date:||Sep 30, 2018|
|Previous Article:||Parent's attitudes and knowledge on oral health in a group of individual with Down syndrome in Turkey.|
|Next Article:||HIFU treatment for fibroadenoma - a clinical study at National Scientific Research Centre, Astana, Kazakhstan.|